Fulcrum Therapeutics appoints Esther Rajavelu as CFO and Treasurer

Fulcrum Therapeutics, Inc.

Esther Rajavelu appointed CFO and Treasurer effective Jan 3, 2022; Peter Thomson ceases as principal financial officer.
Rajavelu receives $435,000 annual base salary, $150,000 signing bonus, and 200,000 stock option at $17.82/share.
Option vests 25% on first anniversary, then 6.25% quarterly over 12 quarters.
Rajavelu has ~20 years life sciences experience including UBS, Oppenheimer, Deutsche Bank, and EY Capital.
Press release highlights two disease-modifying programs (losmapimod for FSHD, FTX-6058 for sickle cell).

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Peter Thomson

Principal Financial Officer

FULC · Fulcrum Therapeutics, Inc.

Effective: 2022-01-03
Successor: Esther Rajavelu
Filed: January 4, 2022, 6:59 PM ET

As a result of Ms. Rajavelu’s appointment, Peter Thomson, the Company’s Vice President, Finance and Accounting, will cease to serve as principal financial officer.

Appointed

Esther Rajavelu

Chief Financial Officer and Treasurer

FULC · Fulcrum Therapeutics, Inc.

Effective: 2022-01-03
Filed: January 4, 2022, 6:59 PM ET

On January 3, 2022, the Board of Directors (the “Board”) of Fulcrum Therapeutics, Inc. (the “Company”) appointed Esther Rajavelu as the Company’s Chief Financial Officer and Treasurer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter Thomson changed role as Principal Financial Officer at Fulcrum Therapeutics, Inc..

Action: ceased
Role: Principal Financial Officer

Exact text from the filing

As a result of Ms. Rajavelu’s appointment, Peter Thomson, the Company’s Vice President, Finance and Accounting, will cease to serve as principal financial officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Esther Rajavelu was appointed as Chief Financial Officer and Treasurer at Fulcrum Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer and Treasurer

Exact text from the filing

On January 3, 2022, the Board of Directors (the “Board”) of Fulcrum Therapeutics, Inc. (the “Company”) appointed Esther Rajavelu as the Company’s Chief Financial Officer and Treasurer, effective immediately.

View on SEC.gov

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-001760

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.